The <i>Neosartorya (Aspergillus) fischeri</i> antifungal protein NFAP2 has low potential to trigger resistance development in <i>Candida albicans in vitro</i>.

ABSTRACT: Due to the increase in the number of drug-resistant Candida albicans strains, new antifungal compounds with limited potential for the development of resistance are urgently needed. NFAP2, an antifungal protein (AFP) secreted by Neosartorya (Aspergillus) fischeri, is a promising candidate. We investigated the ability of C. albicans to develop resistance to NFAP2 in a microevolution experiment compared with generic fluconazole (FLC). C. albicans adapted to only 1× minimum inhibitory concentration (MIC) of NFAP2, which can be considered tolerance rather than resistance, compared with 32× MIC of FLC. Genome analysis revealed non-silent mutations in only two genes in NFAP2-tolerant strains and in several genes in FLC-resistant strains. Tolerance develop

SUBMITTER: Bende G 

PROVIDER: S-EPMC11705825 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature